PCRX vs SPRY
PCRX: Pacira BioSciences is a non-opioid pain management company commercializing injectable, device, and gene therapy treatments for postsurgical and osteoarthritis pain. SPRY: Biopharmaceutical company commercializing neffy, the only FDA-approved needle-free intranasal epinephrine for emergency anaphylaxis treatment.
Side-by-side fundamentals
| Metric | PCRX | SPRY | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $26.47 | $5.76 | |
| Market cap as of 2026-07-30 | $1.0B | $572M | |
| P/E as of 2026-07-30 | 203.64 | n/a | |
| PEG as of 2026-07-30 | 17.75 | -0.00 | SPRY lower |
| Net margin as of 2026-07-30 | +0.7% | -200.0% | PCRX higher |
| Gross margin as of 2026-07-30 | +79.3% | +74.1% | PCRX higher |
| Operating margin as of 2026-07-30 | +0.1% | -204.5% | PCRX higher |
| ROE as of 2026-07-30 | +0.7% | -153.6% | PCRX higher |
| ROA as of 2026-07-30 | +0.4% | -60.9% | PCRX higher |
| Debt / equity as of 2026-07-30 | 0.56 | 1.57 | PCRX lower |
| Revenue growth (YoY) as of 2026-07-30 | +4.6% | +1.9% | PCRX higher |
| Revenue CAGR (3y) SEC XBRL | +2.9% | +300.1% | SPRY higher |
| Beta as of 2026-07-30 | 0.25 | 1.04 | |
| 1-year return as of 2026-07-27 close | +17.4% | -67.8% | PCRX higher |
Fundamentals: market data, as of 2026-07-30. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.